Form 4: Myriad Genetics Executive Reports Stock Transactions

Dale Muzzey, Chief Scientific Officer of Myriad Genetics, reports acquisition and disposal of company stock related to restricted stock units.

Summary

• On March 13, 2025, Dale Muzzey, Chief Scientific Officer of Myriad Genetics, acquired 75,773 shares of common stock at $0, representing restricted stock units.
• On March 14 and 15, 2025, Muzzey disposed of 8,544 and 4,764 shares respectively at a price of $10.07 to cover tax withholding obligations related to vesting restricted stock units.
• Following these transactions, Muzzey directly owns 180,231 shares of Myriad Genetics common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies like Myriad Genetics, similar to filings made by executives at companies like Illumina or Thermo Fisher Scientific.
• The vesting schedule of the restricted stock units, with equal annual installments, is a common compensation structure.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.
• The transactions do not have a material impact on employees, customers, suppliers, or creditors.

Key Dates